Investigational Studies

Editorial: Peter Wehrwein, Editor Advertising: Maureen Dwyer Liberti,     Vice President, Group Publisher Production: Dawn Flook,     Director of Production Services Circulation: Jackie Ott,     Circulation Manager Webmaster: Webmaster … read more at: http://www.managedcaremag.com/news/company-prepares-submit-cannabis-based-epilepsy-treatment-fda

by

LONDON, Sept. 07, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (GWPH) (GWP.L) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference to be […]

by

LONDON, Sept. 07, 2016 — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference to be held at […]

by

LONDON, Sept. 07, 2016 — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference to be held at […]

by

OTTAWA, ONTARIO–(Marketwired – Sept. 6, 2016) – PhytoPain Pharma Inc. (“PhytoPain Pharma” or “PPP“), a subsidiary of GrowPros Cannabis Ventures Inc. (“GrowPros” or the “Company“) (CSE:GCI), today announces the submission to the US Food and Drug Administration (FDA) Office of Orphan Products Development, two applications for Orphan Drug Designation for delta-9-tetrahydrocannibinol and cannabidiol for the […]

by

OTTAWA, ONTARIO–(Marketwired – Sep 6, 2016) – PhytoPain Pharma Inc. (“PhytoPain Pharma” or “PPP“), a subsidiary of GrowPros Cannabis Ventures Inc. (“GrowPros” or the “Company“) (CSE:GCI), today announces the submission to the US Food and Drug Administration (FDA) Office of Orphan Products Development, two applications for Orphan Drug Designation for delta-9-tetrahydrocannibinol and cannabidiol for the […]

by

GW Pharmaceuticals plc (NASDAQ:GWPH, LON:GWP) said it was on track for an NDA (New Drug Application) filing for both its cannabis-derived Dravet Syndrome and Lennox-Gastaut Syndrome indications following positive Phase III trials. “We believe that these Phase III data show that Epidiolex has the potential to provide a robust and clinically meaningful reduction in seizures […]

by

Image Source: Getty Images. Unlike most biopharma stocks, GW Pharmaceuticals (NASDAQ:GWPH), a British company developing marijuana-based medicines, has turned in a stellar 2016. Specifically, the company’s shares are now up by nearly 20% year to date and have simply crushed the performance of the iShares Nasdaq Biotechnology ETF: IBB data by YCharts. GW’s unusual strength […]

by

GW Pharmaceuticals plc (NASDAQ:GWPH, LON:GWP) said it was on track for an NDA (New Drug Application) filing for both its cannabis-derived Dravet Syndrome and Lennox-Gastaut Syndrome indications following positive Phase III trials. “We believe that these Phase III data show that Epidiolex has the potential to provide a robust and clinically meaningful reduction in seizures […]

by

GW Pharmaceuticals plc (NASDAQ:GWPH, LON:GWP) said it was on track for an NDA (New Drug Application) filing for both its cannabis-derived Dravet Syndrome and Lennox-Gastaut Syndrome indications following positive Phase III trials. “We believe that these Phase III data show that Epidiolex has the potential to provide a robust and clinically meaningful reduction in seizures […]

by

WASHINGTON, DC — Regulators at the US Food and Drug Administration for the first time have approved the prescription of a liquid form of dronabinol (synthetic THC), to be marketed under the trade name Syndros. The new drug formula, produced by Insys Therapeutics, is approved for use in patients with AIDS (as an appetite stimulant) and […]

by